Literature DB >> 31897078

High Direct Bilirubin Associated With Levoffoxacin Use in a Neonate.

Amy P Holmes, Charles E Hartis, Laurie J Rollins.   

Abstract

Limited data exist regarding the use of fluoroquinolones in the neonatal population. Levofloxacin has some utility in this population because it is one of a very limited number of antibiotics with activity against Stenotrophomonas maltophilia. We describe the successful treatment of S maltophilia tracheitis in a premature neonate using levofloxacin 10 mg/kg every 24 hours and the subsequent unexpected sharp rise in the direct bilirubin. This case illustrates a previously unrecognized adverse drug effect associated with levofloxacin use in neonates. Copyright Published by the Pediatric Pharmacy Association. All rights reserved. For permissions, mhelms@pediatricpharmacy.org 2020.

Entities:  

Keywords:  Stenotrophomas maltophilia; adverse drug event; hyper-direct bilirubinemia; levofloxacin; neonate

Year:  2020        PMID: 31897078      PMCID: PMC6938287          DOI: 10.5863/1551-6776-25.1.64

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  9 in total

1.  Levofloxacin Use in the Neonate: A Case Series.

Authors:  Brandi D Newby; Kathryn E Timberlake; Lyndsay M Lepp; Tamara Mihic; Deonne A Dersch-Mills
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

3.  Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates.

Authors:  Mehmet Mutlu; Gürdal Yılmaz; Yakup Aslan; Gülçin Bayramoğlu
Journal:  J Microbiol Immunol Infect       Date:  2011-05-24       Impact factor: 4.399

4.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Levofloxacin pharmacokinetics in children.

Authors:  Shuchean Chien; Thomas G Wells; Jeffrey L Blumer; Gregory L Kearns; John S Bradley; Joseph A Bocchini; Jaya Natarajan; Samuel Maldonado; Gary J Noel
Journal:  J Clin Pharmacol       Date:  2005-02       Impact factor: 3.126

Review 8.  The Use of Systemic and Topical Fluoroquinolones.

Authors:  Mary Anne Jackson; Gordon E Schutze
Journal:  Pediatrics       Date:  2016-11       Impact factor: 7.124

Review 9.  Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Authors:  Matthew E Falagas; Antonia C Kastoris; Evridiki K Vouloumanou; Petros I Rafailidis; Anastasios M Kapaskelis; George Dimopoulos
Journal:  Future Microbiol       Date:  2009-11       Impact factor: 3.165

  9 in total
  1 in total

1.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.